Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021) Article
Full Text via DOI: 10.1038/s41591-022-02076-8
Web of Science: 000869357500003